Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Reply to Kostapanos MS, Agouridis AP and Elisaf MS [letter]

Diabetologia

Volumn 58, Issue 8, 2015, Pages 1962-1963

  Cederberg, Henna ^a   Laakso, Markku ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Diabetes; Insulin secretion; Insulin sensitivity and resistance; Statin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; GLUCOSE BLOOD LEVEL; INSULIN;

GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; LETTER; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; PRIORITY JOURNAL; BLOOD; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; SECRETION (PROCESS);

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; INSULIN RESISTANCE; MALE;

EID: 84937525521     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3674-9     Document Type: Letter

References (8)

1. Kostapanos MS, Agouridis AP, Elisaf MS (2015) Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia. doi:10.1007/s00125-015-3633-5
2. Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M (2015) Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 58:1109–1117
3. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS (2009) Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 63:1308–1313
4. Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS (2010) Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 8:612–631
5. Preiss D, Sattar N (2012) Pharmacotherapy: statins and new-onset diabetes—the important questions. Nat Rev Cardiol 9:190–192
6. Zaharan NL, Williams D, Bennett K (2013) Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 75:1118–1124
7. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM (2013) Risk of incident diabetes among patients treated with statins: population based study. BMJ 346:f2610
8. Swerdlow DI, Preiss D, Kuchenbaecker KB et al (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385:351–361